Ethical aspects of new medicines targeted at treatment of RA

被引：2

作者：

Garcia-Porrúa, C ^{[1
]}

González-Gay, MA ^{[1
]}

机构：

[1] Hosp Xeral Calde, Div Rheumatol, Lugo, Spain

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2001年 / 60卷 / 03期

关键词：

D O I：

10.1136/ard.60.3.304

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

页码：304 / 304

页数：1

共 9 条

[1]

Emery P, 1999, LANCET, V353, P1186, DOI 10.1016/S0140-6736(05)74407-X

[2]

Krause D, 2000, ARTHRITIS RHEUM-US, V43, P14, DOI 10.1002/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO

[3]

2-7

[4]

Kreutz G, 1999, ANN RHEUM DIS, V58, P92

[5]

Schiff MH, 1998, ARTHRITIS RHEUM, V41, pS155

[6]

Sharp JT, 2000, ARTHRITIS RHEUM-US, V43, P495, DOI 10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO

[7]

2-U

[8]

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial [J].

Smolen, JS ;

Kalden, JR ;

Scott, DL ;

Rozman, B ;

Kvien, TK ;

Larsen, A ;

Loew-Friedrich, I ;

Oed, C ;

Rosenburg, R .

LANCET, 1999, 353 (9149) :259-266

[9]

Placebo-controlled studies in rheumatoid arthritis: ethical issues [J].

Stein, CM ;

Pincus, T .

LANCET, 1999, 353 (9150) :400-403

← 1 →